Trulieve Commemorates Georgia Medical Cannabis Launch with First Sale

Rhea-AI Summary

Trulieve (NYSE: TRLV) marked Georgia’s expanded medical cannabis program with a ceremonial first sale at its Marietta dispensary. New law SB 220 allows flower and vaporization products for patients 21+ and broadens qualifying conditions. Trulieve is also supplying products to over a dozen licensed independent pharmacies statewide.

Positive

• Georgia law SB 220 adds flower and vaporization products for eligible medical patients
• Trulieve begins supplying medical cannabis to over a dozen Georgia independent pharmacies
• All six Georgia locations host launch events, patient consultations, and product education

Negative

• None.

Market Context

This announcement underscores Georgia growth, adding new flower and vaporization options for patient...

Analysis

This announcement underscores Georgia growth, adding new flower and vaporization options for patients 21+ and leveraging pharmacies after federal rescheduling to Schedule III. Investors may watch patient uptake across Trulieve’s 6 state locations and pharmacy partners.

Key Figures

Law signing date: May 12, 2026 Patient age limit: 21+ years Schedule reclassification: Schedule III +1 more

4 metrics

Law signing date May 12, 2026 Georgia's SB 220 'Putting Georgia's Patients First Act'

Patient age limit 21+ years Eligibility for flower and vaporization products in Georgia

Schedule reclassification Schedule III Federal rescheduling of medical marijuana in April

Georgia locations 6 locations Trulieve dispensaries in Georgia hosting launch-day events

Historical Context

5 past events · Latest: Jun 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 09	Share repurchase	Positive	-8.8%	Authorized up to $50M or 8.5M-share buyback for cancellation.
Jun 05	NYSE uplist	Positive	+17.5%	Approval to list subordinate voting shares on NYSE under TRLV.
May 13	Corporate domestication	Neutral	-3.9%	Plan to move corporate domicile from British Columbia to Delaware.
May 07	Q1 2026 earnings	Positive	-4.9%	Profitable quarter with strong margins and cash generation metrics.
May 05	Store opening	Positive	+5.7%	New Belleview, Florida dispensary opening with promotional offers.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often led to mixed reactions, with some positive catalysts rallying the stock while financial or structural updates saw selling.

Key Terms

schedule iii

1 terms

schedule iii regulatory

"Following federal rescheduling of medical marijuana to Schedule III in April, independent pharmacies..."

A Schedule III classification is a regulatory category for drugs and substances that have a recognized medical use but a moderate risk of dependence or abuse, placing them between higher-risk controlled drugs and over-the-counter medicines. For investors, this matters because it shapes how a product can be manufactured, prescribed, marketed and distributed — affecting potential sales, regulatory hurdles, labeling requirements and legal exposure in the market; think of it as a middle level of control that influences commercial access and compliance costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expanded medical cannabis program broadens patient access in dispensaries and pharmacies

TALLAHASSEE, Fla., July 1, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S, today announced it commemorated the expansion of Georgia's medical cannabis program with a ceremonial first sale this morning at its Marietta location.

The first sale, purchased by retired Army veteran Desi Cleveland, included the Roll One Clutch All in One vape and Modern Flower whole flower — both available for the first time in Georgia — alongside his trusted Trulieve RSO Troches and Momenta Topical Cream.

"I served my country and came home with injuries that affect me every single day. For years, the options I had weren't enough — or came with costs I wasn't willing to pay," said Desi Cleveland, Army veteran from Columbus. "Having access to a vaporized product that provides fast-acting relief when I need it most – alongside the other administration methods I already trust – is something I've been waiting for. Today marks a big step forward for veterans in Georgia."

"Putting Georgia's Patients First Act," or Senate Bill 220, was signed into law by Governor Brian Kemp on May 12, 2026, significantly expanding Georgia's medical cannabis program. The law adds flower and vaporization products for patients 21 and older, expands qualifying conditions to include lupus, HIV, and inflammatory bowel disease, and removes the "end-stage" restrictions that previously limited access for patients living with conditions such as cancer, multiple sclerosis, and Parkinson's disease.

"We are thrilled to provide Georgia patients with a wider variety of products at our dispensaries and independent pharmacies," said Trulieve's Chief Executive Officer Kim Rivers. "We applaud Governor Kemp and the state legislature for recognizing the patient need and addressing it with SB 220."

Following federal rescheduling of medical marijuana to Schedule III in April, independent pharmacies in Georgia with state licensure and DEA registration may sell medical cannabis products to qualified patients. Trulieve has begun providing products to over a dozen pharmacies and expects to expand pharmacy distribution this summer.

"We are proud to partner with Trulieve to offer their trusted products to our patients," said Parth Patel, PharmD, owner of Bonaire Pharmacy. "Pharmacists are trusted healthcare providers, and being able to provide medical cannabis alongside our patients' other medications is a natural extension of the care we already deliver, in their convenient, neighborhood pharmacy setting."

All six Trulieve Georgia locations will host launch-day events featuring patient consultations, product specials, giveaways, and education on program enrollment and new products. For more information on Trulieve's Georgia store locations click here. Follow us on Instagram @Trulieve.GA.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth. Trulieve is listed on the NYSE under the symbol TRLV. For more information, please visit Trulieve.com.

Facebook: @Trulieve   
Instagram: @Trulieve
X: @Trulieve

Investor and Media Contact
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-commemorates-georgia-medical-cannabis-launch-with-first-sale-302814823.html

SOURCE Trulieve Cannabis Corp.

FAQ

What did Trulieve (NYSE: TRLV) announce about the Georgia medical cannabis launch on July 1, 2026?

Trulieve announced a ceremonial first sale marking Georgia’s expanded medical cannabis program at its Marietta location. According to Trulieve, this celebrates broader product access, including flower and vaporization options, for qualified patients aged 21 and older across the state.

How does Georgia Senate Bill 220 affect medical cannabis patients and Trulieve (TRLV)?

Senate Bill 220 significantly expands Georgia’s medical cannabis program. According to Trulieve, it allows flower and vaporization products for patients 21+, adds conditions like lupus, HIV, and inflammatory bowel disease, and removes “end-stage” limits for illnesses such as cancer, multiple sclerosis, and Parkinson’s disease.

Can independent pharmacies in Georgia now sell Trulieve (TRLV) medical cannabis products?

Yes. Following federal rescheduling to Schedule III, licensed independent pharmacies in Georgia may sell medical cannabis to qualified patients. According to Trulieve, it has begun providing products to over a dozen pharmacies and plans to expand pharmacy distribution during the summer.

What products were included in Trulieve’s first expanded medical cannabis sale in Georgia?

The first sale featured Roll One Clutch All in One vape and Modern Flower whole flower, available first-time in Georgia. According to Trulieve, the purchase also included its RSO Troches and Momenta Topical Cream, reflecting multiple administration methods for patients.

How many Trulieve (TRLV) locations in Georgia are involved in the medical cannabis launch events?

All six Trulieve Georgia locations are participating in launch-day events. According to Trulieve, these events include patient consultations, product specials, giveaways, and education on program enrollment and new products to support patients adapting to the expanded medical cannabis options.

What new qualifying conditions are covered under Georgia’s expanded medical cannabis law relevant to Trulieve patients?

The expanded law adds lupus, HIV, and inflammatory bowel disease as qualifying conditions. According to Trulieve, it also removes “end-stage” restrictions for conditions like cancer, multiple sclerosis, and Parkinson’s, enabling more patients to access its medical cannabis products in Georgia.